CNCE
Concert Pharmaceuticals, Inc.
CNCE
CNCE
Delisted
CNCE was delisted on the 3rd of March, 2023.
111 hedge funds and large institutions have $255M invested in Concert Pharmaceuticals, Inc. in 2018 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 42 increasing their positions, 40 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
111
Holders Change
-9
Holders Change %
-7.5%
% of All Funds
2.54%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
42
Reduced
40
Closed
15
Calls
$331K
Puts
$583K
Net Calls
-$252K
Net Calls Change
-$252K
Top Buyers
| 1 |
First Manhattan
New York
|
+$8.38M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.87M |
| 3 |
Renaissance Technologies
New York
|
+$1.84M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.36M |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$1.35M |
Top Sellers
| 1 |
MCM
Matarin Capital Management
New York
|
-$5.33M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$3.34M |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$2.9M |
| 4 |
Millennium Management
New York
|
-$1.76M |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$1.21M |
